Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

27.8%

5 terminated/withdrawn out of 18 trials

Success Rate

68.8%

-17.8% vs industry average

Late-Stage Pipeline

22%

4 trials in Phase 3/4

Results Transparency

82%

9 of 11 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

N/A
12(75.0%)
Phase 4
4(25.0%)
16Total
N/A(12)
Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT06787690Not ApplicableActive Not Recruiting

Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds

Role: lead

NCT06750809Not ApplicableActive Not Recruiting

Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds

Role: lead

NCT05971381Not ApplicableCompleted

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Role: lead

NCT02380612Not ApplicableCompleted

ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries

Role: lead

NCT05386368Phase 4Terminated

RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients

Role: collaborator

NCT04091672Not ApplicableCompleted

RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction

Role: lead

NCT03333941Completed

Continued Access to the Recell® Device for Treatment of Acute Burn Injuries

Role: lead

NCT03626701Not ApplicableTerminated

RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

Role: lead

NCT02994654Not ApplicableCompleted

CONTINUED ACCESS PROTOCOL: Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries

Role: lead

NCT03624192Not ApplicableTerminated

RES Prepared With RECELL® Compared to Conventional Care for Healing of Donor Sites in Ages 1-16 Years

Role: lead

NCT04547998Not ApplicableCompleted

Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions

Role: lead

NCT04271501Not ApplicableTerminated

Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions

Role: lead

NCT02992249Completed

Prospective Evaluation of the ReCell® Autologous Cell Harvesting Device For Specific Compassionate Use Cases

Role: lead

NCT03022019Not ApplicableTerminated

ReNovaCell in Non-segmental Vitiligo

Role: collaborator

NCT02799121Phase 4Completed

A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers

Role: lead

NCT01138917Not ApplicableCompleted

A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries

Role: lead

NCT02458417Phase 4Completed

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

Role: collaborator

NCT01743053Phase 4Completed

A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers

Role: lead

All 18 trials loaded